[go: up one dir, main page]

WO2021234554A3 - Nouvelle composition pour le traitement d'infections virales - Google Patents

Nouvelle composition pour le traitement d'infections virales Download PDF

Info

Publication number
WO2021234554A3
WO2021234554A3 PCT/IB2021/054246 IB2021054246W WO2021234554A3 WO 2021234554 A3 WO2021234554 A3 WO 2021234554A3 IB 2021054246 W IB2021054246 W IB 2021054246W WO 2021234554 A3 WO2021234554 A3 WO 2021234554A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
agent
adjuvant
primary active
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2021/054246
Other languages
English (en)
Other versions
WO2021234554A2 (fr
Inventor
Chandanmal pukhraj BOTHRA
Hemanth Kumar BOTHRA
Elayaraja NATARAJAN
Chitra AJITHAN VARMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nokha Trading LLP
Lyrus Life Sciences Pvt Ltd
Original Assignee
Nokha Trading LLP
Lyrus Life Sciences Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nokha Trading LLP, Lyrus Life Sciences Pvt Ltd filed Critical Nokha Trading LLP
Priority to AU2021276914A priority Critical patent/AU2021276914A1/en
Priority to CA3176914A priority patent/CA3176914A1/fr
Publication of WO2021234554A2 publication Critical patent/WO2021234554A2/fr
Publication of WO2021234554A3 publication Critical patent/WO2021234554A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne la combinaison d'un agent actif primaire et d'un agent mucolytique en tant qu'adjuvant pour le traitement d'infections virales. La présente invention concerne la combinaison d'un agent actif primaire et d'un agent mucolytique en tant qu'adjuvant spécifiquement pour le traitement de la COVID-19. La présente invention concerne le co-conditionnement d'un agent actif primaire et d'un agent mucolytique en tant qu'adjuvant spécifiquement pour le traitement de la COVID-19. La présente invention concerne spécifiquement une composition comprenant une combinaison d'un agent antiviral en tant qu'agent actif primaire et d'un agent mucolytique en tant qu'adjuvant pour le traitement de la COVID-19. La présente invention concerne spécifiquement une composition comprenant une combinaison d'un agent anti-goutte en tant qu'agent actif primaire et d'un agent mucolytique en tant qu'adjuvant pour le traitement de la COVID-19. La présente invention concerne plus spécifiquement la composition comprenant du favipiravir en tant qu'agent actif primaire et de la carbocistéine en tant qu'adjuvant, de la colchicine en tant qu'agent actif primaire et de la carbocistéine en tant qu'adjuvant pour le traitement de la COVID-19.
PCT/IB2021/054246 2020-05-20 2021-05-18 Nouvelle composition pour le traitement d'infections virales Ceased WO2021234554A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021276914A AU2021276914A1 (en) 2020-05-20 2021-05-18 Novel composition for the treatment of viral infections
CA3176914A CA3176914A1 (fr) 2020-05-20 2021-05-18 Nouvelle composition pour le traitement d'infections virales

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ININ202041021211 2020-05-20
IN202041021211 2020-05-20

Publications (2)

Publication Number Publication Date
WO2021234554A2 WO2021234554A2 (fr) 2021-11-25
WO2021234554A3 true WO2021234554A3 (fr) 2022-01-06

Family

ID=78709102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/054246 Ceased WO2021234554A2 (fr) 2020-05-20 2021-05-18 Nouvelle composition pour le traitement d'infections virales

Country Status (3)

Country Link
AU (1) AU2021276914A1 (fr)
CA (1) CA3176914A1 (fr)
WO (1) WO2021234554A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126169A1 (fr) * 2021-12-31 2023-07-06 Unilever Ip Holdings B.V. Utilisation d'un composé de carboxyméthylcystéine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106309420A (zh) * 2015-07-06 2017-01-11 广州白云山医药集团股份有限公司白云山制药总厂 S-(羧甲基)-l-半胱氨酸的新用途
WO2017049060A1 (fr) * 2015-09-16 2017-03-23 Gilead Sciences, Inc. Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106309420A (zh) * 2015-07-06 2017-01-11 广州白云山医药集团股份有限公司白云山制药总厂 S-(羧甲基)-l-半胱氨酸的新用途
WO2017049060A1 (fr) * 2015-09-16 2017-03-23 Gilead Sciences, Inc. Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae

Also Published As

Publication number Publication date
WO2021234554A2 (fr) 2021-11-25
AU2021276914A1 (en) 2022-12-01
CA3176914A1 (fr) 2021-11-25

Similar Documents

Publication Publication Date Title
WO2020198403A3 (fr) Compositions comprenant des polyribonucléotides circulaires modifiés et utilisations associées
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
EP4360651A3 (fr) Compositions glp-1 et leurs utilisations
MX2019009212A (es) Analogos de atazanavir (atv) para tratar infecciones por virus de inmunodeficiencia humana (vih).
CL2021003208A1 (es) Prevención de infecciones por virus altamente patogénico mediante aplicación tópica de povidona-yodada en membranas mucosas
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
WO2020171727A3 (fr) Compositions mucoadhésives et leurs utilisations
MX2025003398A (es) Nuevo compuesto tetraheterociclico
ZA202204941B (en) Cd73 inhibitors
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
BR112022001912A2 (pt) Composições celulares compreendendo vetores virais e métodos de tratamento
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
MX2023007699A (es) Formas solidas de un inhibidor cdk2.
MX2024010625A (es) Compuestos antibioticos, metodos de fabricacion de los mismos, composiciones farmaceuticas conteniendo los mismos y usos de los mismos.
BR112022001365A2 (pt) Formas cristalinas de um inibidor de cd73
MX2022010542A (es) Composiciones y metodos para reducir la expresion de citocinas.
WO2021234554A3 (fr) Nouvelle composition pour le traitement d'infections virales
WO2020091583A3 (fr) Composition cosmétique contenant un antioxydant
BR112022023318A2 (pt) Abridores do canal de potássio maxi-k para o tratamento de distúrbios associados ao x frágil
MX2022000232A (es) Composiciones y metodos para tratar o evitar infecciones oculares con filociclovir.
WO2021226037A8 (fr) Traitement d'infections virales
MX2021013613A (es) Combinacion de compuestos activos.
MX2021006654A (es) Uso de extracto de cocculus hirsutus para tratar dengue.
AR118156A1 (es) Composición de rociado de agente repelente

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3176914

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021276914

Country of ref document: AU

Date of ref document: 20210518

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21808388

Country of ref document: EP

Kind code of ref document: A2